Dr Petros Grivas (Seattle Cancer Care Alliance, Seattle, USA) and Dr Andrea Necchi (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) discuss novel treatment strategies and the latest updates from ASCO 2019 for bladder cancer.
The experts discuss ongoing trials in non-muscle invasive bladder cancer before discussing recent advancements in muscle invasive disease including the potential of neo-adjuvant immunotherapy.
The discussion goes on to cover the potential of antibody drug conjugates for the treatment of patients with metastatic bladder cancer, with the experts commenting on how these therapies may result in a treatment option for unselected patients groups.
Dr Necchi and Dr Grivas conclude the session by discussing the variation in treatment options and genomic testing between different countries, identifying the need for different stakeholders to join the conversation on how best to manage patients with metastatic disease.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
|Current clinical trials in non-muscle invasive bladder cancer|
|Multidisciplinary management of bladder cancer patients|
|PURE 01 trial evaluating pembrolizumab as a neoadjuvant therapy|
|Antibody drug conjugates (ADCs) as a treatment for metastatic bladder cancer|
|Potential application of ADCs as a neoadjuvant therapy and in combination with immunotherapy|
|Improving access to therapy and cancer care|
|Genomic sequencing for bladder cancer patients|
Immuno-Oncology: Advances in Cancer Treatment e-learning course
Take our free e-learning course on the latest developments in immunotherapy here: http://bit.ly/ecancerimmunotherapy